Biovail Target of Grand Jury Probe Over Cardizem

Drug Industry Daily
A A
The U.S. attorney’s office in Boston has notified Biovail it is the target of a federal grand jury investigation into its activities during the 2003 commercial launch of its hypertension and angina drug Cardizem LA.

To View This Article:

Login

Subscribe To Drug Industry Daily